Biohaven Ltd. (BHVN): who owns it and who trades it
As of Nov 16, 2026, BHVN insiders reported 1 purchase worth $145K in the last 12 months. The largest buyer was George C. Clark (Vice president), with $145K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Biohaven
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BHVN
294 funds and institutions reported BHVN shares worth $2.1B at the end of Q2 2026, about 94% of the company. The largest holder is BlackRock, Inc. with 8.8%.
Funds and institutions (13F) 94%Everyone else 6%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.21M | 8.77% | $197M | +18% |
| Montanova Capital, LLC | 10.29M | 6.83% | $153M | No change |
| Stifel Financial Corp | 9.94M | 6.60% | $148M | No change |
| Jupiter Topco LLC | 8.58M | 5.70% | $128M | – |
| Woodline Partners LP | 7.66M | 5.09% | $114M | +2450% |
| State Street Corp | 6.95M | 4.61% | $103M | +5% |
| Infinitum Asset Management, LLC | 6.25M | 4.15% | $93M | No change |
| D. E. Shaw & Co., Inc. | 4.19M | 2.78% | $62.4M | +47% |
| AQR Capital Management LLC | 4.15M | 2.76% | $61.8M | +110% |
| Geode Capital Management, LLC | 3.32M | 2.21% | $49.5M | +20% |
| FMR LLC (Fidelity) | 2.96M | 1.97% | $44.1M | +26% |
| Royalty Pharma Sub-Manager, LLC | 2.94M | 1.95% | $43.7M | No change |
| Cormorant Asset Management, LP | 2.61M | 1.73% | $38.8M | +48% |
| Goldman Sachs Group Inc | 2.58M | 1.72% | $38.4M | +3% |
| UBS Group AG | 2.52M | 1.67% | $37.5M | +77% |
| Vanguard Portfolio Management LLC | 2.49M | 1.65% | $37M | +9% |
| Balyasny Asset Management L.P. | 1.88M | 1.25% | $28M | -23% |
| TCG Crossover Management, LLC | 1.78M | 1.18% | $26.5M | -62% |
| Nuveen, LLC | 1.74M | 1.16% | $26M | +134% |
| Rubric Capital Management LP | 1.72M | 1.14% | $25.6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BHVN insiders reported $145K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | George C. Clark | Vice president | Purchase | 17,000 | $8.52 | $145K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George C. Clark | VP, Chief Accounting Officer | $145K | – | Nov 17, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BHVN short interest
Moderate short interest. 9.9% of BHVN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 38%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 15.01M BHVN shares were sold short, 9.9% of the shares outstanding, down 16.1% from the report before. At the average daily volume of 5.11M shares, buying them all back would take about 2.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 15.01M | 9.94% | -16% | 5.11M | 2.9 |
| Oct 15, 2026 | 17.90M | 11.85% | -6% | 1.95M | 9.2 |
| Sep 30, 2026 | 19.05M | 12.61% | -7% | 2.96M | 6.4 |
| Sep 15, 2026 | 20.45M | 13.54% | +8% | 3.14M | 6.5 |
| Aug 31, 2026 | 19.00M | 12.58% | +7% | 3.97M | 4.8 |
| Aug 14, 2026 | 17.82M | 11.80% | -2% | 1.72M | 10.3 |
| Jul 31, 2026 | 18.19M | 12.08% | -6% | 1.96M | 9.3 |
| Jul 15, 2026 | 19.35M | 12.85% | -5% | 2.56M | 7.5 |
| Jun 30, 2026 | 20.47M | 13.60% | -20% | 4.86M | 4.2 |
| Jun 15, 2026 | 25.50M | 16.94% | +1% | 3.17M | 8.1 |
| May 29, 2026 | 25.25M | 16.77% | +5% | 2.94M | 8.6 |
| May 15, 2026 | 24.10M | 16.00% | -3% | 2.02M | 11.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Biohaven company events
Biohaven filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 22, 2026AnnouncementShared information with investors. Filing
- Oct 15, 2026AgreementBiohaven Ltd., together with its wholly owned subsidiaries, entered into a Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. Filing
- Sep 10, 2026AnnouncementBiohaven Ltd. is providing updates to the BHV-7000 program. Filing
- Aug 26, 2026AgreementBiohaven Bioscience Ireland Limited, a wholly owned subsidiary of Biohaven Ltd., entered into a License Agreement with SK Biopharmaceuticals Co., Ltd. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Aug 7, 2026LeadershipThe Board of Directors of Biohaven Ltd. appointed John Yetimoglu as a director, effective August 6, 2026. Filing
- Jul 9, 2026LeadershipBiohaven Ltd. and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer. Filing
- May 27, 2026AnnouncementShared information with investors. Filing
- May 5, 2026AnnouncementBiohaven Ltd. entered into Amendment No. 2 to the Equity Distribution Agreement, dated October 2, 2023, as previously amended by Amendment No. 1, dated August 16, 2024 (“Amendment No. 1” and, together with the Original Equity Distribution Agreement and Amendment No. 2, the “Equity Distribution… Filing
- May 4, 2026ResultsReleased financial results. Filing
- May 4, 2026VoteReported shareholder vote results. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 7, 2026AnnouncementBiohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Biohaven financials
Famous investors that hold BHVN
4 of the 50 well-known investors we track reported holding BHVN in their latest 13F filing. The largest position is Jim Simons's, worth $6.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 464,852 | $6.2M | 0.0% | +208% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 100,249 | $1.3M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 63,606 | $849K | 0.0% | -31% |
| Israel Englander · Millennium Management | Q3 2026 | 36,728 | $490K | 0.0% | -91% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BHVN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 1.4% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 1.4% |
Questions about Biohaven Ltd. (BHVN) stock
Who owns the most BHVN stock?
The largest reported owner of Biohaven Ltd. (BHVN) is BlackRock, Inc., with 8.8% of the company. In total, 294 funds and institutions reported holding BHVN at the end of Q2 2026, together about 94% of the shares. See the largest owners.
Are BHVN insiders buying or selling?
In the last 12 months, BHVN insiders reported 1 open-market purchase worth $145K and no sales. The latest trade was on Nov 17, 2025. See every trade.
What is the short interest in BHVN?
As of Oct 30, 2026, 15.01M BHVN shares were sold short, 9.9% of the shares outstanding, down 16.1% from the report before. At the average daily volume of 5.11M shares, buying them all back would take about 2.9 trading days (days to cover). See the history.
Which famous investors hold BHVN?
4 of the 50 well-known investors we track reported BHVN in their latest 13F filing, including Jim Simons, Ray Dalio, Paul Tudor Jones. The largest position is worth $6.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.